吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (03): 550-554.doi: 10.13481/j.1671-587x.20170317

• 基础研究 • 上一篇    下一篇

重组鼠白细胞介素18在肝癌小鼠体内的抗肿瘤作用

方艳秋, 米旭光, 李首庆, 魏海峰, 许淑芬, 谭岩   

  1. 吉林省人民医院肿瘤综合治疗科, 吉林 长春 130021
  • 收稿日期:2017-01-15 出版日期:2017-05-28 发布日期:2017-06-01
  • 通讯作者: 谭岩,教授,博士研究生导师(Tel:0431-85595141,E-mail:tanyan49@hotmail.com) E-mail:tanyan49@hotmail.com
  • 作者简介:方艳秋(1968-),女,吉林省长春市人,教授,医学博士,主要从事肿瘤免疫治疗方面的研究。
  • 基金资助:
    吉林省科技厅科技发展计划项目资助课题(20140519018JH);吉林省人社厅省人才开发基金资助课题(2016);吉林省科技厅重点实验室项目资助课题(20122113)

Anti-tumor effect of rmIL-18 in mice with hepatocellular carcinoma

FANG Yanqiu, MI Xuguang, LI Shouqing, WEI Haifeng, XU Shufen, TAN Yan   

  1. Department of Cancer Comprehensive Therapy, Jilin Province People's Hospital, Changchun 130021, China
  • Received:2017-01-15 Online:2017-05-28 Published:2017-06-01

摘要: 目的:探讨不同剂量和输注方式的重组鼠白细胞介素18(rmIL-18)对肝癌小鼠生存时间和肿瘤生长的影响,阐明rmIL-18在体内抗肿瘤的合理应用方式。方法:60只Babl/C小鼠皮下接种小鼠肝癌H22细胞(1×106个),随机分为5μg rmIL-18腹腔内注射治疗组、0.5μg rmIL-18腹腔内注射治疗组、0.5μg rmIL-18肿瘤内注射治疗组、细胞毒性T淋巴细胞(CTL)腹腔内注射治疗组、CTL肿瘤内注射治疗组和生理盐水腹腔注射对照组,每组10只。从接种肿瘤细胞的第10天起,各rmIL-18组小鼠每隔1d进行对应剂量和方式的注射治疗,CTL组小鼠分别腹腔和肿瘤内注射肿瘤特异性CTL(1×106/只),生理盐水腹腔注射对照组小鼠腹腔内注射注射等体积(100μL)生理盐水,共计10次。每周测量小鼠肿瘤直径,并记录生存时间。结果:与0.5μg、5μg rmIL-18腹腔内注射治疗组和生理盐水腹腔注射对照组比较,0.5μg rmIL-18肿瘤内注射治疗组小鼠肿瘤生长速度减慢(P<0.01),小鼠生存时间延长(P<0.01);与0.5μg rmIL-18腹腔内注射治疗组比较,CTL腹腔内注射治疗组小鼠肿瘤生长速度降低(P<0.01),小鼠存活率升高(P<0.01);与0.5μg rmIL-18肿瘤内注射治疗组比较,CTL肿瘤内注射治疗组小鼠肿瘤生长速度降低(P <0.01),小鼠存活率升高(P <0.01)。结论:rmIL-18抗肿瘤作用的最好途径为瘤内注射,并存在剂量依赖性。

关键词: 肝肿瘤, 重组鼠白细胞介素18, 细胞毒性T淋巴细胞

Abstract: Objective: To investigate the effects of different doses and infusion methods of recombinant mouse interleukin-18(rmIL-18) on the survival time and tumor diameter of the mice with hepatocellular carcinoma, and to elucidate the rational application of rmIL-18 in vivo. Methods: A total of 60 Babl/C mice were randomly divided into 5 μg rmIL-18 intraperitoneal injection group, 0.5 μg rmIL-18 intraperitoneal injection group, 0.5 μg rmIL-18 tumor injection group, cytotoxic T lymphocyte(CTL) intraperitoneal injection group, CTL tumor injection group and saline control group;there were 10 mice in each group. From the 10th day of inoculation, the mice in different rmIL-18 groups were injected with the corresponding doses and methods. The mice in different CTL groups were injected with tumor-specific CTL (1×106/mouse) by intraperitoneal and intratumoral injection. The mice in saline control group were injected with an equal volume (100 μL) of saline, the injections were performed 10 times. The diameters of mice were measured weekly and the survival time was recorded. Results: Compared with 5 μg rmIL-18 intraperitoneal injection group, 0.5 μg rmIL-18 intraperitoneal injection group and saline control group, the tumor growth rate of the mice in 0.5 μg rmIL-18 tumor injection group was decreased (P<0.01)and the survival rate of the mice was increased (P<0.01); compared with 0.5 μg rmIL-18 intraperitoneal injection group, the tumor growth rate and the survival rate of the mice in CTL intraperitoneal injection group were decreased (P<0.01);compared with 0.5 μg rmIL-18 tumor injection group,the tumor growth rate and the survival rate of the mice in CTL tumor injection group were decreased (P<0.01). Conclusion: The best way for rmIL-18 anti-tumor effect is tumor injection and the effect has a dose-dependent manner.

Key words: liver neoplasms, recombinant mouse interleukin-18, cytotoxic T lymphocyte

中图分类号: 

  • R735.7